Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in very platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial.
Identifieur interne : 002E60 ( PubMed/Checkpoint ); précédent : 002E59; suivant : 002E61Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in very platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial.
Auteurs : Sven Mahner [Allemagne] ; Werner Meier [Allemagne] ; Andreas Du Bois [Allemagne] ; Chris Brown [Australie] ; Domenica Lorusso [Italie] ; Tiziana Dell'Anna [Italie] ; Jacques Cretin [France] ; Hanne Havsteen [Danemark] ; Paul Bessette [Canada] ; Alain G. Zeimet [Autriche] ; Ignace Vergote [Belgique] ; Paul Vasey [Australie] ; Eric Pujade-Lauraine [France] ; Laurence Gladieff [France] ; Annamaria Ferrero [Italie]Source :
- European journal of cancer (Oxford, England : 1990) [ 1879-0852 ] ; 2015.
Descripteurs français
- KwdFr :
- Adulte, Adulte d'âge moyen, Carboplatine (administration et posologie), Carboplatine (effets indésirables), Composés du platine (usage thérapeutique), Cystadénocarcinome séreux (traitement médicamenteux), Cystadénocarcinome séreux (épidémiologie), Doxorubicine (administration et posologie), Doxorubicine (analogues et dérivés), Doxorubicine (effets indésirables), Effets secondaires indésirables des médicaments (épidémiologie), Femelle, Humains, Paclitaxel (administration et posologie), Paclitaxel (effets indésirables), Polyéthylène glycols (administration et posologie), Polyéthylène glycols (effets indésirables), Récidive, Résistance aux médicaments antinéoplasiques (), Sujet âgé, Sujet âgé de 80 ans ou plus, Traitement médicamenteux adjuvant, Tumeurs de l'ovaire (traitement médicamenteux), Tumeurs de l'ovaire (épidémiologie).
- MESH :
- administration et posologie : Carboplatine, Doxorubicine, Paclitaxel, Polyéthylène glycols.
- analogues et dérivés : Doxorubicine.
- effets indésirables : Carboplatine, Doxorubicine, Paclitaxel, Polyéthylène glycols.
- traitement médicamenteux : Cystadénocarcinome séreux, Tumeurs de l'ovaire.
- usage thérapeutique : Composés du platine.
- épidémiologie : Cystadénocarcinome séreux, Effets secondaires indésirables des médicaments, Tumeurs de l'ovaire.
- Adulte, Adulte d'âge moyen, Femelle, Humains, Récidive, Résistance aux médicaments antinéoplasiques, Sujet âgé, Sujet âgé de 80 ans ou plus, Traitement médicamenteux adjuvant.
English descriptors
- KwdEn :
- Adult, Aged, Aged, 80 and over, Carboplatin (administration & dosage), Carboplatin (adverse effects), Chemotherapy, Adjuvant, Cystadenocarcinoma, Serous (drug therapy), Cystadenocarcinoma, Serous (epidemiology), Doxorubicin (administration & dosage), Doxorubicin (adverse effects), Doxorubicin (analogs & derivatives), Drug Resistance, Neoplasm (drug effects), Drug-Related Side Effects and Adverse Reactions (epidemiology), Female, Humans, Middle Aged, Ovarian Neoplasms (drug therapy), Ovarian Neoplasms (epidemiology), Paclitaxel (administration & dosage), Paclitaxel (adverse effects), Platinum Compounds (therapeutic use), Polyethylene Glycols (administration & dosage), Polyethylene Glycols (adverse effects), Recurrence.
- MESH :
- chemical , administration & dosage : Carboplatin, Doxorubicin, Paclitaxel, Polyethylene Glycols.
- chemical , adverse effects : Carboplatin, Doxorubicin, Paclitaxel, Polyethylene Glycols.
- chemical , analogs & derivatives : Doxorubicin.
- drug effects : Drug Resistance, Neoplasm.
- drug therapy : Cystadenocarcinoma, Serous, Ovarian Neoplasms.
- epidemiology : Cystadenocarcinoma, Serous, Drug-Related Side Effects and Adverse Reactions, Ovarian Neoplasms.
- chemical , therapeutic use : Platinum Compounds.
- Adult, Aged, Aged, 80 and over, Chemotherapy, Adjuvant, Female, Humans, Middle Aged, Recurrence.
Abstract
To perform a subset analysis of patients with very platinum-sensitive recurrent ovarian cancer (ROC) enrolled in the phase III CALYPSO trial.
DOI: 10.1016/j.ejca.2014.11.017
PubMed: 25534295
Affiliations:
- Allemagne, Australie, Autriche, Belgique, Canada, Danemark, France, Italie
- Hovedstaden, Languedoc-Roussillon, Lombardie, Midi-Pyrénées, Nouvelle-Galles du Sud, Occitanie (région administrative), Piémont, Île-de-France
- Copenhague, Milan, Nîmes, Paris, Sydney, Toulouse, Turin
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:25534295Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in very platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial.</title><author><name sortKey="Mahner, Sven" sort="Mahner, Sven" uniqKey="Mahner S" first="Sven" last="Mahner">Sven Mahner</name><affiliation wicri:level="1"><nlm:affiliation>Arbeitsgemeinschaft Gynäkologische Onkologie, AGO Study Group (AGO) and University Medical Center Hamburg-Eppendorf, Germany. Electronic address: Sven.Mahner@gmx.de.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Arbeitsgemeinschaft Gynäkologische Onkologie, AGO Study Group (AGO) and University Medical Center Hamburg-Eppendorf</wicri:regionArea><wicri:noRegion>AGO Study Group (AGO) and University Medical Center Hamburg-Eppendorf</wicri:noRegion><wicri:noRegion>AGO Study Group (AGO) and University Medical Center Hamburg-Eppendorf</wicri:noRegion><wicri:noRegion>AGO Study Group (AGO) and University Medical Center Hamburg-Eppendorf</wicri:noRegion></affiliation></author><author><name sortKey="Meier, Werner" sort="Meier, Werner" uniqKey="Meier W" first="Werner" last="Meier">Werner Meier</name><affiliation wicri:level="1"><nlm:affiliation>Arbeitsgemeinschaft Gynäkologische Onkologie, AGO Study Group (AGO) and Evangelisches Krankenhaus Düsseldorf, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Arbeitsgemeinschaft Gynäkologische Onkologie, AGO Study Group (AGO) and Evangelisches Krankenhaus Düsseldorf</wicri:regionArea><wicri:noRegion>AGO Study Group (AGO) and Evangelisches Krankenhaus Düsseldorf</wicri:noRegion><wicri:noRegion>AGO Study Group (AGO) and Evangelisches Krankenhaus Düsseldorf</wicri:noRegion><wicri:noRegion>AGO Study Group (AGO) and Evangelisches Krankenhaus Düsseldorf</wicri:noRegion></affiliation></author><author><name sortKey="Du Bois, Andreas" sort="Du Bois, Andreas" uniqKey="Du Bois A" first="Andreas" last="Du Bois">Andreas Du Bois</name><affiliation wicri:level="1"><nlm:affiliation>Arbeitsgemeinschaft Gynäkologische Onkologie, AGO Study Group (AGO) and Kliniken Essen-Mitte, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Arbeitsgemeinschaft Gynäkologische Onkologie, AGO Study Group (AGO) and Kliniken Essen-Mitte</wicri:regionArea><wicri:noRegion>AGO Study Group (AGO) and Kliniken Essen-Mitte</wicri:noRegion><wicri:noRegion>AGO Study Group (AGO) and Kliniken Essen-Mitte</wicri:noRegion><wicri:noRegion>AGO Study Group (AGO) and Kliniken Essen-Mitte</wicri:noRegion></affiliation></author><author><name sortKey="Brown, Chris" sort="Brown, Chris" uniqKey="Brown C" first="Chris" last="Brown">Chris Brown</name><affiliation wicri:level="3"><nlm:affiliation>ANZGOG-NHMRC, Sydney, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>ANZGOG-NHMRC, Sydney</wicri:regionArea><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region></placeName></affiliation></author><author><name sortKey="Lorusso, Domenica" sort="Lorusso, Domenica" uniqKey="Lorusso D" first="Domenica" last="Lorusso">Domenica Lorusso</name><affiliation wicri:level="3"><nlm:affiliation>Multicenter Italian Trials in Ovarian Cancer and gynecologic malignancies group (MITO) and Istituto Nazionale dei Tumori, Milan, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Multicenter Italian Trials in Ovarian Cancer and gynecologic malignancies group (MITO) and Istituto Nazionale dei Tumori, Milan</wicri:regionArea><placeName><settlement type="city">Milan</settlement><region nuts="2">Lombardie</region></placeName></affiliation></author><author><name sortKey="Dell Anna, Tiziana" sort="Dell Anna, Tiziana" uniqKey="Dell Anna T" first="Tiziana" last="Dell'Anna">Tiziana Dell'Anna</name><affiliation wicri:level="1"><nlm:affiliation>Mario Negri Gynecologic Oncology Group (MANGO) and Ospedale San Gerardo, Monza, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Mario Negri Gynecologic Oncology Group (MANGO) and Ospedale San Gerardo, Monza</wicri:regionArea><wicri:noRegion>Monza</wicri:noRegion></affiliation></author><author><name sortKey="Cretin, Jacques" sort="Cretin, Jacques" uniqKey="Cretin J" first="Jacques" last="Cretin">Jacques Cretin</name><affiliation wicri:level="3"><nlm:affiliation>Group d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO) and Clinique Valdegourue, Nimes, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Group d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO) and Clinique Valdegourue, Nimes</wicri:regionArea><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Languedoc-Roussillon</region><settlement type="city">Nîmes</settlement></placeName></affiliation></author><author><name sortKey="Havsteen, Hanne" sort="Havsteen, Hanne" uniqKey="Havsteen H" first="Hanne" last="Havsteen">Hanne Havsteen</name><affiliation wicri:level="3"><nlm:affiliation>Nordic Society of Gynecological Oncology (NSGO) and Copenhagen University, Copenhagen, Denmark.</nlm:affiliation><country xml:lang="fr">Danemark</country><wicri:regionArea>Nordic Society of Gynecological Oncology (NSGO) and Copenhagen University, Copenhagen</wicri:regionArea><placeName><settlement type="city">Copenhague</settlement><region type="région" nuts="2">Hovedstaden</region></placeName></affiliation></author><author><name sortKey="Bessette, Paul" sort="Bessette, Paul" uniqKey="Bessette P" first="Paul" last="Bessette">Paul Bessette</name><affiliation wicri:level="1"><nlm:affiliation>National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG) and Universite de Sherbrooke, Sherbrooke, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG) and Universite de Sherbrooke, Sherbrooke</wicri:regionArea><wicri:noRegion>Sherbrooke</wicri:noRegion></affiliation></author><author><name sortKey="Zeimet, Alain G" sort="Zeimet, Alain G" uniqKey="Zeimet A" first="Alain G" last="Zeimet">Alain G. Zeimet</name><affiliation wicri:level="1"><nlm:affiliation>Arbeitsgemeinschaft Gynäkologische Onkologie Österreich (AGO-Austria) and Innsbruck University, Innsbruck, Austria.</nlm:affiliation><country xml:lang="fr">Autriche</country><wicri:regionArea>Arbeitsgemeinschaft Gynäkologische Onkologie Österreich (AGO-Austria) and Innsbruck University, Innsbruck</wicri:regionArea><wicri:noRegion>Innsbruck</wicri:noRegion></affiliation></author><author><name sortKey="Vergote, Ignace" sort="Vergote, Ignace" uniqKey="Vergote I" first="Ignace" last="Vergote">Ignace Vergote</name><affiliation wicri:level="1"><nlm:affiliation>European Organisation for Research and Treatment of Cancer (EORTC) and University Hospital Leuven, Leuven, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>European Organisation for Research and Treatment of Cancer (EORTC) and University Hospital Leuven, Leuven</wicri:regionArea><wicri:noRegion>Leuven</wicri:noRegion></affiliation></author><author><name sortKey="Vasey, Paul" sort="Vasey, Paul" uniqKey="Vasey P" first="Paul" last="Vasey">Paul Vasey</name><affiliation wicri:level="1"><nlm:affiliation>Australia New Zealand Gynecological Oncology Group (ANZGOG) and Wesley Medical Centre, Brisbane, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Australia New Zealand Gynecological Oncology Group (ANZGOG) and Wesley Medical Centre, Brisbane</wicri:regionArea><wicri:noRegion>Brisbane</wicri:noRegion></affiliation></author><author><name sortKey="Pujade Lauraine, Eric" sort="Pujade Lauraine, Eric" uniqKey="Pujade Lauraine E" first="Eric" last="Pujade-Lauraine">Eric Pujade-Lauraine</name><affiliation wicri:level="3"><nlm:affiliation>Group d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO) and Universite Paris Descartes, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Group d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO) and Universite Paris Descartes, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Gladieff, Laurence" sort="Gladieff, Laurence" uniqKey="Gladieff L" first="Laurence" last="Gladieff">Laurence Gladieff</name><affiliation wicri:level="3"><nlm:affiliation>Group d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO) and Institut Claudius Regaud, Toulouse, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Group d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO) and Institut Claudius Regaud, Toulouse</wicri:regionArea><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Ferrero, Annamaria" sort="Ferrero, Annamaria" uniqKey="Ferrero A" first="Annamaria" last="Ferrero">Annamaria Ferrero</name><affiliation wicri:level="3"><nlm:affiliation>Mario Negri Gynecologic Oncology Group (MANGO) and Ospedale Ordine Mauriziano di Torino, Turin, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Mario Negri Gynecologic Oncology Group (MANGO) and Ospedale Ordine Mauriziano di Torino, Turin</wicri:regionArea><placeName><settlement type="city">Turin</settlement><region type="région" nuts="2">Piémont</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="RBID">pubmed:25534295</idno><idno type="pmid">25534295</idno><idno type="doi">10.1016/j.ejca.2014.11.017</idno><idno type="wicri:Area/PubMed/Corpus">003020</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">003020</idno><idno type="wicri:Area/PubMed/Curation">002F39</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002F39</idno><idno type="wicri:Area/PubMed/Checkpoint">002F39</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002F39</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in very platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial.</title><author><name sortKey="Mahner, Sven" sort="Mahner, Sven" uniqKey="Mahner S" first="Sven" last="Mahner">Sven Mahner</name><affiliation wicri:level="1"><nlm:affiliation>Arbeitsgemeinschaft Gynäkologische Onkologie, AGO Study Group (AGO) and University Medical Center Hamburg-Eppendorf, Germany. Electronic address: Sven.Mahner@gmx.de.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Arbeitsgemeinschaft Gynäkologische Onkologie, AGO Study Group (AGO) and University Medical Center Hamburg-Eppendorf</wicri:regionArea><wicri:noRegion>AGO Study Group (AGO) and University Medical Center Hamburg-Eppendorf</wicri:noRegion><wicri:noRegion>AGO Study Group (AGO) and University Medical Center Hamburg-Eppendorf</wicri:noRegion><wicri:noRegion>AGO Study Group (AGO) and University Medical Center Hamburg-Eppendorf</wicri:noRegion></affiliation></author><author><name sortKey="Meier, Werner" sort="Meier, Werner" uniqKey="Meier W" first="Werner" last="Meier">Werner Meier</name><affiliation wicri:level="1"><nlm:affiliation>Arbeitsgemeinschaft Gynäkologische Onkologie, AGO Study Group (AGO) and Evangelisches Krankenhaus Düsseldorf, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Arbeitsgemeinschaft Gynäkologische Onkologie, AGO Study Group (AGO) and Evangelisches Krankenhaus Düsseldorf</wicri:regionArea><wicri:noRegion>AGO Study Group (AGO) and Evangelisches Krankenhaus Düsseldorf</wicri:noRegion><wicri:noRegion>AGO Study Group (AGO) and Evangelisches Krankenhaus Düsseldorf</wicri:noRegion><wicri:noRegion>AGO Study Group (AGO) and Evangelisches Krankenhaus Düsseldorf</wicri:noRegion></affiliation></author><author><name sortKey="Du Bois, Andreas" sort="Du Bois, Andreas" uniqKey="Du Bois A" first="Andreas" last="Du Bois">Andreas Du Bois</name><affiliation wicri:level="1"><nlm:affiliation>Arbeitsgemeinschaft Gynäkologische Onkologie, AGO Study Group (AGO) and Kliniken Essen-Mitte, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Arbeitsgemeinschaft Gynäkologische Onkologie, AGO Study Group (AGO) and Kliniken Essen-Mitte</wicri:regionArea><wicri:noRegion>AGO Study Group (AGO) and Kliniken Essen-Mitte</wicri:noRegion><wicri:noRegion>AGO Study Group (AGO) and Kliniken Essen-Mitte</wicri:noRegion><wicri:noRegion>AGO Study Group (AGO) and Kliniken Essen-Mitte</wicri:noRegion></affiliation></author><author><name sortKey="Brown, Chris" sort="Brown, Chris" uniqKey="Brown C" first="Chris" last="Brown">Chris Brown</name><affiliation wicri:level="3"><nlm:affiliation>ANZGOG-NHMRC, Sydney, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>ANZGOG-NHMRC, Sydney</wicri:regionArea><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region></placeName></affiliation></author><author><name sortKey="Lorusso, Domenica" sort="Lorusso, Domenica" uniqKey="Lorusso D" first="Domenica" last="Lorusso">Domenica Lorusso</name><affiliation wicri:level="3"><nlm:affiliation>Multicenter Italian Trials in Ovarian Cancer and gynecologic malignancies group (MITO) and Istituto Nazionale dei Tumori, Milan, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Multicenter Italian Trials in Ovarian Cancer and gynecologic malignancies group (MITO) and Istituto Nazionale dei Tumori, Milan</wicri:regionArea><placeName><settlement type="city">Milan</settlement><region nuts="2">Lombardie</region></placeName></affiliation></author><author><name sortKey="Dell Anna, Tiziana" sort="Dell Anna, Tiziana" uniqKey="Dell Anna T" first="Tiziana" last="Dell'Anna">Tiziana Dell'Anna</name><affiliation wicri:level="1"><nlm:affiliation>Mario Negri Gynecologic Oncology Group (MANGO) and Ospedale San Gerardo, Monza, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Mario Negri Gynecologic Oncology Group (MANGO) and Ospedale San Gerardo, Monza</wicri:regionArea><wicri:noRegion>Monza</wicri:noRegion></affiliation></author><author><name sortKey="Cretin, Jacques" sort="Cretin, Jacques" uniqKey="Cretin J" first="Jacques" last="Cretin">Jacques Cretin</name><affiliation wicri:level="3"><nlm:affiliation>Group d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO) and Clinique Valdegourue, Nimes, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Group d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO) and Clinique Valdegourue, Nimes</wicri:regionArea><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Languedoc-Roussillon</region><settlement type="city">Nîmes</settlement></placeName></affiliation></author><author><name sortKey="Havsteen, Hanne" sort="Havsteen, Hanne" uniqKey="Havsteen H" first="Hanne" last="Havsteen">Hanne Havsteen</name><affiliation wicri:level="3"><nlm:affiliation>Nordic Society of Gynecological Oncology (NSGO) and Copenhagen University, Copenhagen, Denmark.</nlm:affiliation><country xml:lang="fr">Danemark</country><wicri:regionArea>Nordic Society of Gynecological Oncology (NSGO) and Copenhagen University, Copenhagen</wicri:regionArea><placeName><settlement type="city">Copenhague</settlement><region type="région" nuts="2">Hovedstaden</region></placeName></affiliation></author><author><name sortKey="Bessette, Paul" sort="Bessette, Paul" uniqKey="Bessette P" first="Paul" last="Bessette">Paul Bessette</name><affiliation wicri:level="1"><nlm:affiliation>National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG) and Universite de Sherbrooke, Sherbrooke, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG) and Universite de Sherbrooke, Sherbrooke</wicri:regionArea><wicri:noRegion>Sherbrooke</wicri:noRegion></affiliation></author><author><name sortKey="Zeimet, Alain G" sort="Zeimet, Alain G" uniqKey="Zeimet A" first="Alain G" last="Zeimet">Alain G. Zeimet</name><affiliation wicri:level="1"><nlm:affiliation>Arbeitsgemeinschaft Gynäkologische Onkologie Österreich (AGO-Austria) and Innsbruck University, Innsbruck, Austria.</nlm:affiliation><country xml:lang="fr">Autriche</country><wicri:regionArea>Arbeitsgemeinschaft Gynäkologische Onkologie Österreich (AGO-Austria) and Innsbruck University, Innsbruck</wicri:regionArea><wicri:noRegion>Innsbruck</wicri:noRegion></affiliation></author><author><name sortKey="Vergote, Ignace" sort="Vergote, Ignace" uniqKey="Vergote I" first="Ignace" last="Vergote">Ignace Vergote</name><affiliation wicri:level="1"><nlm:affiliation>European Organisation for Research and Treatment of Cancer (EORTC) and University Hospital Leuven, Leuven, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>European Organisation for Research and Treatment of Cancer (EORTC) and University Hospital Leuven, Leuven</wicri:regionArea><wicri:noRegion>Leuven</wicri:noRegion></affiliation></author><author><name sortKey="Vasey, Paul" sort="Vasey, Paul" uniqKey="Vasey P" first="Paul" last="Vasey">Paul Vasey</name><affiliation wicri:level="1"><nlm:affiliation>Australia New Zealand Gynecological Oncology Group (ANZGOG) and Wesley Medical Centre, Brisbane, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Australia New Zealand Gynecological Oncology Group (ANZGOG) and Wesley Medical Centre, Brisbane</wicri:regionArea><wicri:noRegion>Brisbane</wicri:noRegion></affiliation></author><author><name sortKey="Pujade Lauraine, Eric" sort="Pujade Lauraine, Eric" uniqKey="Pujade Lauraine E" first="Eric" last="Pujade-Lauraine">Eric Pujade-Lauraine</name><affiliation wicri:level="3"><nlm:affiliation>Group d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO) and Universite Paris Descartes, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Group d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO) and Universite Paris Descartes, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Gladieff, Laurence" sort="Gladieff, Laurence" uniqKey="Gladieff L" first="Laurence" last="Gladieff">Laurence Gladieff</name><affiliation wicri:level="3"><nlm:affiliation>Group d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO) and Institut Claudius Regaud, Toulouse, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Group d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO) and Institut Claudius Regaud, Toulouse</wicri:regionArea><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Ferrero, Annamaria" sort="Ferrero, Annamaria" uniqKey="Ferrero A" first="Annamaria" last="Ferrero">Annamaria Ferrero</name><affiliation wicri:level="3"><nlm:affiliation>Mario Negri Gynecologic Oncology Group (MANGO) and Ospedale Ordine Mauriziano di Torino, Turin, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Mario Negri Gynecologic Oncology Group (MANGO) and Ospedale Ordine Mauriziano di Torino, Turin</wicri:regionArea><placeName><settlement type="city">Turin</settlement><region type="région" nuts="2">Piémont</region></placeName></affiliation></author></analytic><series><title level="j">European journal of cancer (Oxford, England : 1990)</title><idno type="eISSN">1879-0852</idno><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Carboplatin (administration & dosage)</term><term>Carboplatin (adverse effects)</term><term>Chemotherapy, Adjuvant</term><term>Cystadenocarcinoma, Serous (drug therapy)</term><term>Cystadenocarcinoma, Serous (epidemiology)</term><term>Doxorubicin (administration & dosage)</term><term>Doxorubicin (adverse effects)</term><term>Doxorubicin (analogs & derivatives)</term><term>Drug Resistance, Neoplasm (drug effects)</term><term>Drug-Related Side Effects and Adverse Reactions (epidemiology)</term><term>Female</term><term>Humans</term><term>Middle Aged</term><term>Ovarian Neoplasms (drug therapy)</term><term>Ovarian Neoplasms (epidemiology)</term><term>Paclitaxel (administration & dosage)</term><term>Paclitaxel (adverse effects)</term><term>Platinum Compounds (therapeutic use)</term><term>Polyethylene Glycols (administration & dosage)</term><term>Polyethylene Glycols (adverse effects)</term><term>Recurrence</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Carboplatine (administration et posologie)</term><term>Carboplatine (effets indésirables)</term><term>Composés du platine (usage thérapeutique)</term><term>Cystadénocarcinome séreux (traitement médicamenteux)</term><term>Cystadénocarcinome séreux (épidémiologie)</term><term>Doxorubicine (administration et posologie)</term><term>Doxorubicine (analogues et dérivés)</term><term>Doxorubicine (effets indésirables)</term><term>Effets secondaires indésirables des médicaments (épidémiologie)</term><term>Femelle</term><term>Humains</term><term>Paclitaxel (administration et posologie)</term><term>Paclitaxel (effets indésirables)</term><term>Polyéthylène glycols (administration et posologie)</term><term>Polyéthylène glycols (effets indésirables)</term><term>Récidive</term><term>Résistance aux médicaments antinéoplasiques ()</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term><term>Traitement médicamenteux adjuvant</term><term>Tumeurs de l'ovaire (traitement médicamenteux)</term><term>Tumeurs de l'ovaire (épidémiologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Carboplatin</term><term>Doxorubicin</term><term>Paclitaxel</term><term>Polyethylene Glycols</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Carboplatin</term><term>Doxorubicin</term><term>Paclitaxel</term><term>Polyethylene Glycols</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Doxorubicin</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Carboplatine</term><term>Doxorubicine</term><term>Paclitaxel</term><term>Polyéthylène glycols</term></keywords><keywords scheme="MESH" qualifier="analogues et dérivés" xml:lang="fr"><term>Doxorubicine</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Drug Resistance, Neoplasm</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Cystadenocarcinoma, Serous</term><term>Ovarian Neoplasms</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Carboplatine</term><term>Doxorubicine</term><term>Paclitaxel</term><term>Polyéthylène glycols</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Cystadenocarcinoma, Serous</term><term>Drug-Related Side Effects and Adverse Reactions</term><term>Ovarian Neoplasms</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Platinum Compounds</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Cystadénocarcinome séreux</term><term>Tumeurs de l'ovaire</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Composés du platine</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Cystadénocarcinome séreux</term><term>Effets secondaires indésirables des médicaments</term><term>Tumeurs de l'ovaire</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Chemotherapy, Adjuvant</term><term>Female</term><term>Humans</term><term>Middle Aged</term><term>Recurrence</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Femelle</term><term>Humains</term><term>Récidive</term><term>Résistance aux médicaments antinéoplasiques</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term><term>Traitement médicamenteux adjuvant</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">To perform a subset analysis of patients with very platinum-sensitive recurrent ovarian cancer (ROC) enrolled in the phase III CALYPSO trial.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25534295</PMID><DateCreated><Year>2015</Year><Month>02</Month><Day>04</Day></DateCreated><DateCompleted><Year>2015</Year><Month>04</Month><Day>15</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-0852</ISSN><JournalIssue CitedMedium="Internet"><Volume>51</Volume><Issue>3</Issue><PubDate><Year>2015</Year><Month>Feb</Month></PubDate></JournalIssue><Title>European journal of cancer (Oxford, England : 1990)</Title><ISOAbbreviation>Eur. J. Cancer</ISOAbbreviation></Journal><ArticleTitle>Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in very platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial.</ArticleTitle><Pagination><MedlinePgn>352-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ejca.2014.11.017</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0959-8049(14)01142-3</ELocationID><Abstract><AbstractText Label="AIM" NlmCategory="OBJECTIVE">To perform a subset analysis of patients with very platinum-sensitive recurrent ovarian cancer (ROC) enrolled in the phase III CALYPSO trial.</AbstractText><AbstractText Label="PATIENTS AND METHODS" NlmCategory="METHODS">The international non-inferiority trial enrolled women with ROC that relapsed >6 months following first- or second-line platinum- and paclitaxel-based therapies. Patients were randomised to CD [carboplatin-pegylated liposomal doxorubicin (PLD)] or CP (carboplatin-paclitaxel) and stratified by treatment-free interval (TFI). In this analysis, patients with a TFI>24 months were analysed separately for progression free survival (PFS), the primary endpoint of CALYPSO, overall survival (OS) and safety.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 259 very platinum-sensitive patients were included (n=131, CD; n=128, CP). Median PFS was 12.0 months for the CD arm and 12.3 months for CP [HR=1.05 (95% CI, 0.79-1.40); P=0.73 for superiority] and median OS was 40.2 months for CD and 43.9 for CP [HR=1.18 (95% CI 0.85-1.63); P=0.33 for superiority]. Overall response rates were 42% and 38%, respectively (P=0.46). Toxicities were more common with CP versus CD, including grade 3/4 neutropenia (40.8% versus 27.5%; P=0.025), nausea (4.8% versus 3.1%; P=0.47), allergic reaction (8% versus 3.1%; P=0.082) sensory neuropathy (4.8% versus 2.3%; P=0.27) and grade 2 alopecia (88% versus 9.2%; P<0.001). Grade 3/4 thrombocytopenia (12.2% versus 3.2%; P=0.007) and mucositis (2.3% versus 0%; P=0.089) were more common with CD. Grade 3/4 hand-foot syndrome occurred rarely with CD (3 patients versus 0 in CP arm; P=0.089).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">CP and CD were equally effective treatment regimens for patients with very platinum-sensitive ROC. The favourable risk-benefit profile suggests carboplatin-PLD as treatment of choice for these patients.</AbstractText><CopyrightInformation>Copyright © 2014 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mahner</LastName><ForeName>Sven</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Arbeitsgemeinschaft Gynäkologische Onkologie, AGO Study Group (AGO) and University Medical Center Hamburg-Eppendorf, Germany. Electronic address: Sven.Mahner@gmx.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meier</LastName><ForeName>Werner</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Arbeitsgemeinschaft Gynäkologische Onkologie, AGO Study Group (AGO) and Evangelisches Krankenhaus Düsseldorf, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>du Bois</LastName><ForeName>Andreas</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Arbeitsgemeinschaft Gynäkologische Onkologie, AGO Study Group (AGO) and Kliniken Essen-Mitte, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brown</LastName><ForeName>Chris</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>ANZGOG-NHMRC, Sydney, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lorusso</LastName><ForeName>Domenica</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Multicenter Italian Trials in Ovarian Cancer and gynecologic malignancies group (MITO) and Istituto Nazionale dei Tumori, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dell'Anna</LastName><ForeName>Tiziana</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Mario Negri Gynecologic Oncology Group (MANGO) and Ospedale San Gerardo, Monza, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cretin</LastName><ForeName>Jacques</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Group d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO) and Clinique Valdegourue, Nimes, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Havsteen</LastName><ForeName>Hanne</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Nordic Society of Gynecological Oncology (NSGO) and Copenhagen University, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bessette</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG) and Universite de Sherbrooke, Sherbrooke, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zeimet</LastName><ForeName>Alain G</ForeName><Initials>AG</Initials><AffiliationInfo><Affiliation>Arbeitsgemeinschaft Gynäkologische Onkologie Österreich (AGO-Austria) and Innsbruck University, Innsbruck, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vergote</LastName><ForeName>Ignace</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>European Organisation for Research and Treatment of Cancer (EORTC) and University Hospital Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vasey</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Australia New Zealand Gynecological Oncology Group (ANZGOG) and Wesley Medical Centre, Brisbane, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pujade-Lauraine</LastName><ForeName>Eric</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Group d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO) and Universite Paris Descartes, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gladieff</LastName><ForeName>Laurence</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Group d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO) and Institut Claudius Regaud, Toulouse, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferrero</LastName><ForeName>Annamaria</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Mario Negri Gynecologic Oncology Group (MANGO) and Ospedale Ordine Mauriziano di Torino, Turin, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>12</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eur J Cancer</MedlineTA><NlmUniqueID>9005373</NlmUniqueID><ISSNLinking>0959-8049</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017671">Platinum Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C506643">liposomal doxorubicin</NameOfSubstance></Chemical><Chemical><RegistryNumber>30IQX730WE</RegistryNumber><NameOfSubstance UI="D011092">Polyethylene Glycols</NameOfSubstance></Chemical><Chemical><RegistryNumber>80168379AG</RegistryNumber><NameOfSubstance UI="D004317">Doxorubicin</NameOfSubstance></Chemical><Chemical><RegistryNumber>BG3F62OND5</RegistryNumber><NameOfSubstance UI="D016190">Carboplatin</NameOfSubstance></Chemical><Chemical><RegistryNumber>P88XT4IS4D</RegistryNumber><NameOfSubstance UI="D017239">Paclitaxel</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016190" MajorTopicYN="N">Carboplatin</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017024" MajorTopicYN="N">Chemotherapy, Adjuvant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018284" MajorTopicYN="N">Cystadenocarcinoma, Serous</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004317" MajorTopicYN="N">Doxorubicin</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000031" MajorTopicYN="Y">analogs & derivatives</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019008" MajorTopicYN="N">Drug Resistance, Neoplasm</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064420" MajorTopicYN="N">Drug-Related Side Effects and Adverse Reactions</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010051" MajorTopicYN="N">Ovarian Neoplasms</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017239" MajorTopicYN="N">Paclitaxel</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017671" MajorTopicYN="N">Platinum Compounds</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011092" MajorTopicYN="N">Polyethylene Glycols</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CALYPSO</Keyword><Keyword MajorTopicYN="N">Carboplatin</Keyword><Keyword MajorTopicYN="N">Ovarian cancer</Keyword><Keyword MajorTopicYN="N">Paclitaxel</Keyword><Keyword MajorTopicYN="N">Pegylated liposomal doxorubicin</Keyword><Keyword MajorTopicYN="N">Very platinum-sensitive</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>09</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2014</Year><Month>11</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>11</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>12</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>12</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>4</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25534295</ArticleId><ArticleId IdType="pii">S0959-8049(14)01142-3</ArticleId><ArticleId IdType="doi">10.1016/j.ejca.2014.11.017</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Allemagne</li><li>Australie</li><li>Autriche</li><li>Belgique</li><li>Canada</li><li>Danemark</li><li>France</li><li>Italie</li></country><region><li>Hovedstaden</li><li>Languedoc-Roussillon</li><li>Lombardie</li><li>Midi-Pyrénées</li><li>Nouvelle-Galles du Sud</li><li>Occitanie (région administrative)</li><li>Piémont</li><li>Île-de-France</li></region><settlement><li>Copenhague</li><li>Milan</li><li>Nîmes</li><li>Paris</li><li>Sydney</li><li>Toulouse</li><li>Turin</li></settlement></list><tree><country name="Allemagne"><noRegion><name sortKey="Mahner, Sven" sort="Mahner, Sven" uniqKey="Mahner S" first="Sven" last="Mahner">Sven Mahner</name></noRegion><name sortKey="Du Bois, Andreas" sort="Du Bois, Andreas" uniqKey="Du Bois A" first="Andreas" last="Du Bois">Andreas Du Bois</name><name sortKey="Meier, Werner" sort="Meier, Werner" uniqKey="Meier W" first="Werner" last="Meier">Werner Meier</name></country><country name="Australie"><region name="Nouvelle-Galles du Sud"><name sortKey="Brown, Chris" sort="Brown, Chris" uniqKey="Brown C" first="Chris" last="Brown">Chris Brown</name></region><name sortKey="Vasey, Paul" sort="Vasey, Paul" uniqKey="Vasey P" first="Paul" last="Vasey">Paul Vasey</name></country><country name="Italie"><region name="Lombardie"><name sortKey="Lorusso, Domenica" sort="Lorusso, Domenica" uniqKey="Lorusso D" first="Domenica" last="Lorusso">Domenica Lorusso</name></region><name sortKey="Dell Anna, Tiziana" sort="Dell Anna, Tiziana" uniqKey="Dell Anna T" first="Tiziana" last="Dell'Anna">Tiziana Dell'Anna</name><name sortKey="Ferrero, Annamaria" sort="Ferrero, Annamaria" uniqKey="Ferrero A" first="Annamaria" last="Ferrero">Annamaria Ferrero</name></country><country name="France"><region name="Occitanie (région administrative)"><name sortKey="Cretin, Jacques" sort="Cretin, Jacques" uniqKey="Cretin J" first="Jacques" last="Cretin">Jacques Cretin</name></region><name sortKey="Gladieff, Laurence" sort="Gladieff, Laurence" uniqKey="Gladieff L" first="Laurence" last="Gladieff">Laurence Gladieff</name><name sortKey="Pujade Lauraine, Eric" sort="Pujade Lauraine, Eric" uniqKey="Pujade Lauraine E" first="Eric" last="Pujade-Lauraine">Eric Pujade-Lauraine</name></country><country name="Danemark"><region name="Hovedstaden"><name sortKey="Havsteen, Hanne" sort="Havsteen, Hanne" uniqKey="Havsteen H" first="Hanne" last="Havsteen">Hanne Havsteen</name></region></country><country name="Canada"><noRegion><name sortKey="Bessette, Paul" sort="Bessette, Paul" uniqKey="Bessette P" first="Paul" last="Bessette">Paul Bessette</name></noRegion></country><country name="Autriche"><noRegion><name sortKey="Zeimet, Alain G" sort="Zeimet, Alain G" uniqKey="Zeimet A" first="Alain G" last="Zeimet">Alain G. Zeimet</name></noRegion></country><country name="Belgique"><noRegion><name sortKey="Vergote, Ignace" sort="Vergote, Ignace" uniqKey="Vergote I" first="Ignace" last="Vergote">Ignace Vergote</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002E60 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 002E60 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:25534295
|texte= Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in very platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:25534295" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |